David Lebwohl
Impact in
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Cancer Research top 0.5%
Papers in
- Oncology 37
- Cancer Treatment and Pharmacology 23
- Colorectal Cancer Treatments and Studies 9
- HER2/EGFR in Cancer Research 4
-
- Renal cell carcinoma treatment 4
- Prostate Cancer Treatment and Research 4
- Co-authors
- Renzo Canetta (4 shared papers)Eric Van Cutsem (7 shared papers)William J. Berg (7 shared papers)Andrea Kay (4 shared papers)James C. Yao (5 shared papers)Marianne Pavel (2 shared papers)Kjell Öberg (2 shared papers)Edward M. Wolin (2 shared papers)
- Journals
- Journal of Clinical Oncology (20 papers)The Lancet (4 papers)New England Journal of Medicine (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)Investigational New Drugs (3 papers)
- Partner nations
- United StatesGermanySwitzerland
In The Last Decade
David Lebwohl
74 papers receiving 12.6k citations
David Lebwohl's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 4.8k
- Cancer Research 1.5k
- Neurology 1.4k
- Pulmonary and Respiratory Medicine 3.0k
- Epidemiology 2.8k
Countries citing papers authored by David Lebwohl
This map shows the geographic impact of David Lebwohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lebwohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lebwohl more than expected).
Fields of papers citing papers by David Lebwohl
This network shows the impact of papers produced by David Lebwohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lebwohl. The network helps show where David Lebwohl may publish in the future.
Co-authors
The 25 scholars most cited alongside David Lebwohl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2345 |
| 2 | Everolimus for Advanced Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 2096 |
| 3 | Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2011 | 777 |
| 4 | Clinical development of platinum complexes in cancer therapy: an historical perspective and an update Hit paper breakdown → | 1998 | 668 |
| 5 | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2013 | 643 |
| 6 | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Hit paper breakdown → | 2012 | 586 |
| 7 | Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. Hit paper breakdown → | 1987 | 559 |
| 8 | Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Hit paper breakdown → | 2004 | 529 |
| 9 | Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial Hit paper breakdown → | 2009 | 488 |
| 10 | 2008 | 426 | |
| 11 | Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Hit paper breakdown → | 2013 | 389 |
| 12 | Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study Hit paper breakdown → | 2013 | 382 |
| 13 | 2007 | 225 | |
| 14 | 2009 | 191 | |
| 15 | 2007 | 174 | |
| 16 | 2005 | 167 | |
| 17 | 1995 | 166 | |
| 18 | 2011 | 139 | |
| 19 | 2005 | 128 | |
| 20 | 2011 | 125 |
About David Lebwohl
David Lebwohl is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Epidemiology, having authored 75 papers that have together received 12.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (23 papers), Colorectal Cancer Treatments and Studies (9 papers), Breast Cancer Treatment Studies (5 papers), Angiogenesis and VEGF in Cancer (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Renal cell carcinoma treatment (4 papers), HER2/EGFR in Cancer Research (4 papers) and Prostate Cancer Treatment and Research (4 papers). The work is most often cited by research in Oncology (4.8k citations), Cancer Research (1.5k citations), Neurology (1.4k citations), Pulmonary and Respiratory Medicine (3.0k citations) and Epidemiology (2.8k citations). David Lebwohl has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Renzo Canetta, Eric Van Cutsem, William J. Berg, Andrea Kay, James C. Yao, Marianne Pavel, Kjell Öberg, Edward M. Wolin, T Haas and Jeremie Lincy. Their work appears in journals such as Journal of Clinical Oncology, The Lancet, New England Journal of Medicine, Cancer Chemotherapy and Pharmacology and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.